Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $23.7 million.

  • Lineage Cell Therapeutics' Total Non-Current Liabilities changed N/A to $23.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.7 million, marking a year-over-year change of. This contributed to the annual value of $30.0 million for FY2024, which is 2295.36% down from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Total Non-Current Liabilities stood at $23.7 million.
  • Lineage Cell Therapeutics' 5-year Total Non-Current Liabilities high stood at $83.6 million for Q4 2021, and its period low was $10.9 million during Q1 2021.
  • Over the past 5 years, Lineage Cell Therapeutics' median Total Non-Current Liabilities value was $39.7 million (recorded in 2023), while the average stood at $39.7 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Total Non-Current Liabilities soared by 57514.74% in 2021, and later tumbled by 3813.94% in 2022.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Total Non-Current Liabilities stood at $83.6 million in 2021, then plummeted by 38.14% to $51.7 million in 2022, then fell by 24.61% to $39.0 million in 2023, then decreased by 22.95% to $30.0 million in 2024, then decreased by 21.21% to $23.7 million in 2025.
  • Its last three reported values are $23.7 million in Q3 2025, $24.9 million for Q2 2025, and $28.0 million during Q1 2025.